Pharmaceutical
Biotechnology
Biopharmaceutical

Alexion Pharmaceuticals

$127.15
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.82 (1.45%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ALXN and other stocks, options, ETFs, and crypto commission-free!

About

Alexion Pharmaceuticals, Inc. Common Stock, also called Alexion Pharmaceuticals, is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Read More Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA.

Employees
2,656
Headquarters
Boston, Massachusetts
Founded
1992
Market Cap
28.51B
Price-Earnings Ratio
69.68
Dividend Yield
0.00
Average Volume
1.51M
High Today
$128.26
Low Today
$125.70
Open Price
$126.27
Volume
450.40K
52 Week High
$141.86
52 Week Low
$92.56

Collections

Pharmaceutical
Biotechnology
Biopharmaceutical
Health
Therapy
Technology
US
North America

News

Yahoo Finance3h

Why Is Alexion Down 6.3% Since Last Earnings Report?

It has been about a month since the last earnings report for Alexion Pharmaceuticals (ALXN). Shares have lost about 6.3% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Alexion due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Alexion Q1 Earnings Beat Estimates, ...

3
MarketWatchMay 23

Alexion Pharmaceuticals Inc.

The U.S. Justice Department said Thursday that Jazz Pharmaceuticals PLC , Alexion Pharmaceuticals Inc. and Lundbeck LLC have agreed to pay a combined $122.6 million to settle allegations that they paid kickbacks through co-pay assistance foundations for their own products. The companies violated the False Claims Act by illegally paying the Medicare or Civilian Health and Medical Program (ChampVA) copays for their own products, through purportedly independent foundations that the companies used as conduits, ...

85
IB TimesMay 19

Top 5 New Drug Launches Of 2019 -- And The Biotech Stocks That Could Win Big

Every year, biopharmaceutical companies introduce new drugs to the market. Some of these drugs become big winners. Others don't. Market research company EvaluatePharma analyzed all of the drugs that could launch in 2019. The company then projected how much each drug could potentially generate by 2024. Alexion Pharmaceuticals (NASDAQ:ALXN), AbbVie (NYSE:ABBV), Aimmune Therapeutics (NASDAQ:AIMT), and bluebird bio (NASDAQ:BLUE) came out on top in EvaluatePharma's ranking of the top five new drug launches expe...

1,679

Earnings

$1.28
$1.65
$2.02
$2.39
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Jul 25, Pre-Market

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.